Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : 16z
Deal Size : $65.0 million
Deal Type : Series A Financing
Details : The DUBTAC platform was developed to therapeutically target these degraded proteins by removing ubiquitin chains, from specific proteins to stop their degradation and stabilize their levels for therapeutic benefit.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 28, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : 16z
Deal Size : $65.0 million
Deal Type : Series A Financing
Reset All
